The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating the tolerability of a simultaneous focal boost to the gross tumor in prostate SABR: A toxicity and quality-of-life comparison of two prospective trials.
 
Yasir Alayed
No Relationships to Disclose
 
Melanie Davidson
No Relationships to Disclose
 
William Chu
No Relationships to Disclose
 
Stanley K. Liu
No Relationships to Disclose
 
Chia-Lin Tseng
No Relationships to Disclose
 
Patrick Cheung
Research Funding - Pfizer (Inst); Sanofi (Inst)
 
Danny Vesprini
Honoraria - Tersera
Travel, Accommodations, Expenses - Elekta
 
Hans T. Chung
Honoraria - Bayer; Tersera
Consulting or Advisory Role - Elekta
 
Gerard Morton
No Relationships to Disclose
 
Hima Bindu Musunuru
No Relationships to Disclose
 
Ananth Ravi
No Relationships to Disclose
 
Renee Korol
No Relationships to Disclose
 
Andrea Deabreu
No Relationships to Disclose
 
Kristina Commisso
No Relationships to Disclose
 
Zeeba Bhounr
No Relationships to Disclose
 
Laura D'alimonte
No Relationships to Disclose
 
Nicole Mittmann
No Relationships to Disclose
 
Alice Dragomir
Research Funding - Sanofi (Inst)
 
Liying Zhang
No Relationships to Disclose
 
Andrew Loblaw
Honoraria - Abbvie; Astellas Pharma; Bayer; Janssen Oncology; Sanofi; Tersera
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Janssen Oncology; Sanofi; TerSera
Research Funding - Tersera
Patents, Royalties, Other Intellectual Property - Prostate immobilization device (GU-Lok)
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology; Sanofi; Tersera